Foliculitis decalvante por sobreinfección bacteriana secundaria a erlotinib
暂无分享，去创建一个
[1] M. Anadkat,et al. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections , 2016, Supportive Care in Cancer.
[2] D. Stewart,et al. Erlotinib‐induced folliculitis decalvans , 2013, Clinical and experimental dermatology.
[3] J. Fischer,et al. Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation , 2013, Science Translational Medicine.
[4] L. Wiznia,et al. Unique presentations of epidermal growth factor receptor inhibitor-induced papulopustular eruption related to bacterial superinfection. , 2013, Dermatology online journal.
[5] Qiang Xu,et al. Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway. , 2011, Toxicology and applied pharmacology.
[6] R. Hoekzema,et al. Folliculitis decalvans associated with erlotinib , 2010, Clinical and experimental dermatology.
[7] M. Lacouture,et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. , 2010, Journal of the National Cancer Institute.
[8] M. Gipps,et al. Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. , 2008, Clinical lung cancer.